{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T03:13:27Z","timestamp":1794971607725,"version":"4.9.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s13555-025-01453-8","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T05:12:42Z","timestamp":1748927562000},"page":"2295-2305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jo\u00e3o","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jo\u00e3o","family":"Paiva Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Lazaridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose-Manuel","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel","family":"Alvarenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Farinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Munera-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Rankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Caccavale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Mariel","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Pires Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina Ioanna","family":"Daponte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Silvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Prignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Kolios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatios","family":"Gregoriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Rompoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Gkalpakiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Chiricozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"issue":"9","key":"1453_CR1","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/jamadermatol.2024.2192","volume":"160","author":"AM Drucker","year":"2024","unstructured":"Drucker AM, Lam M, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update. JAMA Dermatol. 2024;160(9):936\u201344.","journal-title":"JAMA Dermatol"},{"key":"1453_CR2","doi-asserted-by":"publisher","first-page":"42275","DOI":"10.2340\/actadv.v105.42275","volume":"105","author":"L Calabrese","year":"2025","unstructured":"Calabrese L, Cinotti E, D\u2019Onghia M, et al. Effectiveness and safety of tralokinumab in atopic dermatitis: 1-year results from a real-world multicentre study. Acta Derm Venereol. 2025;105:42275.","journal-title":"Acta Derm Venereol"},{"key":"1453_CR3","doi-asserted-by":"crossref","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: systemic therapy-naive versus -experienced patients. J Am Acad Dermatol. 2025;92(5):1049\u201355.","DOI":"10.1016\/j.jaad.2025.01.052"},{"issue":"12","key":"1453_CR4","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/ced\/llae208","volume":"49","author":"S Ferrucci","year":"2024","unstructured":"Ferrucci S, Tavecchio S, Maronese CA, et al. Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients. Clin Exp Dermatol. 2024;49(12):1561\u201372.","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"1453_CR5","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1453_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/bjd\/ljad393","volume":"190","author":"AM Drucker","year":"2024","unstructured":"Drucker AM, Lam M, Elsawi R, et al. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. Br J Dermatol. 2024;190(2):184\u201390.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1453_CR7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s13555-024-01143-x","volume":"14","author":"T Torres","year":"2024","unstructured":"Torres T, Petersen AS, Ivens U, et al. Matching-adjusted indirect comparison of the efficacy at week\u00a032 of tralokinumab and dupilumab in the treatment of moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024;14(4):983\u201392.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"11","key":"1453_CR8","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1111\/jdv.20229","volume":"38","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham M, Katoh N, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38(11):2139\u201348.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1453_CR9","doi-asserted-by":"publisher","first-page":"2308682","DOI":"10.1080\/09546634.2024.2308682","volume":"35","author":"ML Schaarschmidt","year":"2024","unstructured":"Schaarschmidt ML, Kromer D, Wellmann P, Peitsch WK, Kromer C. Patients\u2019 preferences for systemic treatment of atopic dermatitis: safety and efficacy count the most. J Dermatolog Treat. 2024;35(1):2308682.","journal-title":"J Dermatolog Treat"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01453-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01453-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01453-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:00:34Z","timestamp":1757178034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01453-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1453"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01453-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"5 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Amgen, Apogee Therapeutics, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Johnson & Johnson Innovative Medicine, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, STADA and UCB. Jensen Yeung has been an advisor, consultant, speaker, and\/or investigator for AbbVie, Amgen, Anacor, Apogee, Arcutis, Astellas, Bausche, Baxalta, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Coherus, Dermira, Forward, Fresenius Kabi, Galderma, Incyte, Janssen, LEO Pharma, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Xenon. Vimal H. Prajapati has been an advisor, consultant, and\/or speaker for: AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cipher, CorEvitas, Eczema Society of Canada, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Incyte, JAMP Pharma, J&J Innovative Medicine, Janssen, Johnson & Johnson, LEO Pharma, Medexus, Novartis, Organon, Pediapharm, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Tribute, UCB, and Valeant; investigator for: AbbVie, AnaptysBio, Apogee Therapeutics, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, J&J Innovative Medicine, Janssen, LEO Pharma, Meiji Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, Takeda, and UCB; received grants from: AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme. Anna Balato has received fees from Abbvie, Almirall, Amgen, BMS, Boehringer Ingelheim, Eli Lilly, LeoPharma, Novartis, UCB. Stefano Caccavale has received fees from Abbvie, Aristo pharma Italy srl, Novartis, Eli Lilly, Boehringer Ingelheim. Maria Jo\u00e3o Cruz has been an advisor, consultant, speaker, and\/or investigator for AbbVie, Almirall, Beiersdorf, Eli Lilly, Galderma, La Roche-Posay, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals Inc., Sanofi. Francesca Prignano served as advisory board member and consultant and has received fees and speaker\u2019s honoraria or has participated in clinical trials for AbbVie, Almirall, Leo Pharma, Eli Lilly, Janssen, Novartis, Biogen, Sanofi Genzyme, UCB, Boehringer Ingelheim. Niccol\u00f2 Gori served as advisory board member and received honoraria for lectures for AbbVie, Sanofi, and LEO Pharma. Andrea Chiricozzi has served as advisory board member and consultant and has received fees and speaker\u2019s honoraria or has participated in clinical trials for AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Leo Pharma, Lilly, Janssen, Novartis, Pfizer, and Sanofi Genzyme. Ketty Peris has served on advisory board, received honoraria for lectures and\/or research grants for Abbvie, Almirall, Lilly, Galderma, Leo Pharma, Pierre Fabre, Novartis, Sanofi, Sun Pharma, Janssen. Simone Ribero has been an advisor, consultant, speaker, and\/or investigator for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and UCB. Michela Ortoncelli has been an advisor, consultant, speaker, and\/or investigator for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and UCB. Elizabeth Lazaridou has received grants and speaker\u2019s honoraria and\/or has participated in advisory meetings and clinical trials for Abbvie, Novartis, Pfizer, Sanofi, Leo Pharma, Eli Lilly, Galderma, Janssen, UCB, Amgen, Pierre Fabre, Loreal, Boehringer Ingelheim, Incyte. Angelo Valerio Marzano reports consultancy\/advisory boards disease-relevant honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Incyte, Leopharma, Novartis, Pfizer, Sanofi, and UCB. Silvia Mariel Ferrucci reports consultancy\/advisory boards disease-relevant honoraria from Amgen, Sanofi, Novartis, Lilly, Leo Pharma, Abbvie, Novartis, Menarini. Spyridon Gkalpakiotis has served as a consultant, speaker, or investigator for AbbVie, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, Sanofi and UCB. Pedro Herranz has received grants and speaker\u2019s honoraria and\/or has participated in advisory meetings and clinical for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi Genzyme, Takeda, UCB. Antonios G.A. Kolios has served as an investigator, speaker, and\/or advisor for AbbVie, Abbott, AstraZeneca, Janssen, Eli Lilly, MSD, Pfizer, Celgene, Novartis, Actelion, Leo, Amgen, Alk-Abello, UCB, and does not hold any shares or other financial interest in any pharmaceutical company. Jose-Manuel Carrascosa has received grants and speaker\u2019s honoraria and\/or has participated in advisory meetings and clinical for AbbVie, Novartis, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Roche, Sandoz, Sanofi Genzyme, UCB. Maria Jo\u00e3o Paiva Lopes has received grants and speaker\u2019s honoraria and\/or has participated in advisory meetings and clinical AbbVie, Almirall, Boehringer Ingelheim, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer, Sanofi-Genzyme, Viatris. Jos\u00e9 Miguel Alvarenga has nothing to disclose. Pedro Farinha has nothing to disclose. Bruno Duarte has nothing to disclose. Monica Munera-Campos has nothing to disclose. Siddhartha Sood has nothing to disclose. Brian D. Rankin has nothing to disclose. Gilberto Pires Rosa has nothing to disclose. Athina Ioanna Daponte has nothing to disclose. Gianmarco Silvi has nothing to disclose. Stamatios Gregoriou has nothing to disclose. Natalia Rompoti has nothing to disclose. Tiago Torres, Jose-Manuel Carrascosa and Stamatios Gregoriou are Editorial Board members of Dermatology and Therapy. Tiago Torres, Jose-Manuel Carrascosa and Stamatios Gregoriou were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The present study was conducted in accordance with the Declaration of Helsinki, initially published in 1964 on Ethical Principles for Medical Research Involving Human Subjects, and after approval by the local ethical committees. Patient consent was exempted due to the retrospective nature of the study and the use of de-identified, anonymized and aggregated data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}